A Phase 3 interventional study of Coagulation Factor VIIa (Recombinant) in Hemophilia, sponsored by Laboratoire français de Fractionnement et de Biotechnologies. Completed at 9 sites in 6 countries. Open to male participants aged 6 Months to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-25.
Sponsored by Laboratoire français de Fractionnement et de Biotechnologies · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 3, and was the 18th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
American Thrombosis and Hemostasis Network · Sites in United States
Ages 12–100
By country, each count listing its studies:
recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 6 Months to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2016.
This study's enrollment of 12 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 24 across the 19 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
Laboratoire français de Fractionnement et de Biotechnologies is the lead sponsor of 16 studies on the registry; none are open to participants now.
Laboratoire français de Fractionnement et de Biotechnologies has 4 studies filed under Hemophilia A — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study, PerSept 3, is to evaluate LR769 for the prevention of excessive bleeding and achievement of hemostasis in congenital hemophilia A or B patients who have inhibitors to Factor VIII or Factor IX , are aged 6 months to 75 years, inclusive; and who are undergoing elective surgical or other invasive procedures. Administration of LR769 will be performed just prior to surgery/procedure and will be repeated during and after the surgery/procedure to achieve and maintain adequate hemostasis as determined by the investigator's judgment.
This study is an international, multicenter, single-arm, Phase 3 study. Patients aged 6 months to 75 years, inclusive, who have congenital hemophilia A or B with inhibitors to Factor VIII or Factor IX and who are scheduled for an elective surgical or other invasive procedure will be enrolled. Both major and minor surgical or other invasive procedures are allowed in the study.
Initial Treatment: Regardless of procedure, patients who meet all eligibility criteria will receive an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For a minor elective surgery or other minor invasive procedure, a dose of 75 μg/kg will be used as the initial dose; for a major elective surgery or other major invasive procedure, a dose of 200 μg/kg of LR769 will be used as the initial dose. For both minor and major procedures, administration will be repeated no more frequently than every 2 hours (±5 minutes) at a dose of 75 μg/kg during and after surgery or invasive procedure.
Treatment for Major Surgical Procedures: The initial dose of LR769 will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure. The minimum duration of LR769 treatment for major procedures will be 5 days and dosing frequency will be followed according to the guidelines specified in the protocol.
Treatment for Minor Surgical or Other Invasive Procedures: The initial dose of LR769 will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours. The minimum duration of LR769 infusion for minor procedures will be 2 days, except for certain procedures that may not require this duration of treatment to achieve hemostasis as noted in the protocol. Dosing frequency will be according to the guidelines specified in protocol for minor surgical or other invasive procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet the following criteria to be enrolled in this study:
have one of the following:
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
Biological: Coagulation Factor VIIa (Recombinant)
LR769
Percentage of Surgical or Other Invasive Procedures Defined as "Good" or "Excellent" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality of the Assessments Performed on the Patient
The final assessment was performed by the investigator at the study center 48 hours after the last dose of LR769 and was based upon the totality of the assessments performed on the patient at each time point. Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required. Good: postoperative blood loss greater, but not substantially greater than expected, following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion.
Time frame: 48 (±4) hours after the last administration of LR769
Percentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee
Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required
Time frame: 24 hours after procedure completion
Percentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee
Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required
Time frame: 72 hours after procedure completion
| Milestone | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) |
|---|---|---|
| Started | 6 | 6 |
| Completed | 5 | 5 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The final assessment was performed by the investigator at the study center 48 hours after the last dose of LR769 and was based upon the totality of the assessments performed on the patient at each time point. Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required. Good: postoperative blood loss greater, but not substantially greater than expected, following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion.
| Surgeries | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) |
|---|---|---|
| Successes | 4 | 5 |
| Failures | 2 | 0 |
Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required
| Surgeries | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) |
|---|---|---|
| Successes | 4 | 6 |
| Failures | 0 | 0 |
Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required
| Surgeries | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) |
|---|---|---|
| Successes | 5 | 2 |
| Failures | 0 | 0 |
Collected over Adverse Events (AEs) were collected from the time of signing of the informed consent/assent until resolution or 30 days after the last dose of LR769 or early termination, whichever came first.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) |
|---|---|---|
| Haemorrhagic AnaemiaBlood and lymphatic system disorders | 1/6 | 0/6 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 1/6 | 0/6 |
| Event | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) |
|---|---|---|
| Procedural PainInjury, poisoning and procedural complications | 5/6 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 0/6 |
| Anaemia PostoperativeInjury, poisoning and procedural complications | 2/6 | 0/6 |
| Wound SecretionInjury, poisoning and procedural complications | 1/6 | 2/6 |
| Abdominal PainGastrointestinal disorders | 1/6 | 0/6 |
| NauseaGastrointestinal disorders | 1/6 | 0/6 |
| Catheter Site PainGeneral disorders | 0/6 | 1/6 |
| Postoperative Wound InfectionInfections and infestations | 1/6 | 0/6 |
| Post Procedural HaematomaInjury, poisoning and procedural complications | 1/6 | 0/6 |
| Post Procedural HaemorrhageInjury, poisoning and procedural complications | 1/6 | 1/6 |
| Age, Categorical(Participants) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| <=18 years | 2 | 4 | 6 |
| Between 18 and 65 years | 4 | 2 | 6 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| Mean | 34.0 ± 20.19 | 16.0 ± 15.52 | 25.0 ± 19.57 |
| Sex: Female, Male(Participants) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 6 | 6 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 6 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| Ukraine | 3 | 3 | 6 |
| South Africa | 1 | 3 | 4 |
| Mexico | 1 | 0 | 1 |
| Russia | 1 | 0 | 1 |
| Weight(kg) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| Mean | 54.17 ± 25.974 | 36.72 ± 21.506 | 45.44 ± 24.494 |
| Height(cm) | Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg) | Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg) | Total |
|---|---|---|---|
| Mean | 156.3 ± 22.50 | 137.8 ± 34.02 | 147.1 ± 29.13 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2016 to primary completion in Aug 2017, 11 months.
Results were first posted in Sep 2019, 2 years 1 month after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa
Laboratoire français de Fractionnement et de Biotechnologies